Swiss National Bank lifted its stake in shares of bluebird bio Inc (NASDAQ:BLUE) by 2.6% in the 2nd quarter, according to its most recent 13F filing with the Securities and Exchange Commission. The fund owned 102,207 shares of the biotechnology company’s stock after buying an additional 2,600 shares during the quarter. Swiss National Bank owned about 0.19% of bluebird bio worth $13,001,000 at the end of the most recent reporting period.
Other large investors also recently modified their holdings of the company. Envestnet Asset Management Inc. grew its stake in shares of bluebird bio by 9.8% during the 2nd quarter. Envestnet Asset Management Inc. now owns 10,281 shares of the biotechnology company’s stock worth $1,308,000 after purchasing an additional 915 shares during the period. Stanley Laman Group Ltd. acquired a new position in shares of bluebird bio during the 2nd quarter worth $243,000. Advisor Group Inc. grew its stake in shares of bluebird bio by 25.4% during the 2nd quarter. Advisor Group Inc. now owns 1,411 shares of the biotechnology company’s stock worth $180,000 after purchasing an additional 286 shares during the period. Aperio Group LLC grew its stake in shares of bluebird bio by 4.4% during the 2nd quarter. Aperio Group LLC now owns 12,447 shares of the biotechnology company’s stock worth $1,583,000 after purchasing an additional 530 shares during the period. Finally, KBC Group NV grew its stake in shares of bluebird bio by 6.4% during the 2nd quarter. KBC Group NV now owns 18,581 shares of the biotechnology company’s stock worth $2,364,000 after purchasing an additional 1,120 shares during the period.
A number of equities analysts have recently weighed in on BLUE shares. Gabelli reaffirmed a “buy” rating on shares of bluebird bio in a research note on Friday, July 19th. Piper Jaffray Companies set a $120.00 price objective on shares of bluebird bio and gave the stock a “hold” rating in a research report on Friday, June 14th. BidaskClub lowered shares of bluebird bio from a “hold” rating to a “sell” rating in a research report on Friday, August 2nd. Morgan Stanley decreased their price objective on shares of bluebird bio from $143.00 to $136.00 and set an “equal weight” rating on the stock in a research report on Tuesday, August 6th. Finally, JPMorgan Chase & Co. reiterated a “buy” rating and issued a $195.00 price objective on shares of bluebird bio in a research report on Thursday, June 13th. One research analyst has rated the stock with a sell rating, ten have given a hold rating, ten have issued a buy rating and two have assigned a strong buy rating to the stock. The stock presently has a consensus rating of “Buy” and a consensus price target of $154.13.
bluebird bio (NASDAQ:BLUE) last released its quarterly earnings data on Thursday, August 1st. The biotechnology company reported ($3.55) EPS for the quarter, missing the consensus estimate of ($3.04) by ($0.51). The business had revenue of $13.30 million during the quarter, compared to analysts’ expectations of $13.13 million. bluebird bio had a negative return on equity of 35.90% and a negative net margin of 1,158.04%. bluebird bio’s quarterly revenue was up 68.4% on a year-over-year basis. During the same quarter in the prior year, the firm earned ($2.91) earnings per share. As a group, sell-side analysts predict that bluebird bio Inc will post -13.22 EPS for the current fiscal year.
In other bluebird bio news, insider David Davidson sold 7,660 shares of the company’s stock in a transaction dated Friday, July 5th. The shares were sold at an average price of $129.47, for a total value of $991,740.20. Following the transaction, the insider now directly owns 38,946 shares in the company, valued at approximately $5,042,338.62. The transaction was disclosed in a legal filing with the SEC, which is available through the SEC website. Also, insider Jeffrey T. Walsh sold 500 shares of the company’s stock in a transaction dated Tuesday, August 20th. The shares were sold at an average price of $124.00, for a total transaction of $62,000.00. Following the completion of the transaction, the insider now owns 41,421 shares in the company, valued at $5,136,204. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 13,260 shares of company stock worth $1,690,667. 3.00% of the stock is owned by insiders.
bluebird bio Profile
bluebird bio, Inc, a clinical-stage biotechnology company, focuses on developing transformative gene therapies for severe genetic diseases and cancer. Its product candidates in severe genetic diseases include LentiGlobin, which is in various clinical studies for the treatment of transfusion-dependent ß-thalassemia and severe sickle cell disease; and Lenti-D that is in Phase II/III clinical trials for the treatment of cerebral adrenoleukodystrophy, a rare hereditary neurological disorder.
Read More: Why are percentage decliners important?
Want to see what other hedge funds are holding BLUE? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for bluebird bio Inc (NASDAQ:BLUE).
Receive News & Ratings for bluebird bio Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for bluebird bio and related companies with MarketBeat.com's FREE daily email newsletter.